💨 Abstract
Novo Nordisk and Valo Health have expanded their 2023 agreement to develop new treatments for cardiometabolic diseases using AI. The partnership aims to develop up to 20 drugs for obesity, type 2 diabetes, and cardiovascular diseases. The deal could potentially yield Valo near-term payments of up to $190 million and milestone payments of $4.6
Courtesy: theprint.in
Summarized by Einstein Beta 🤖
Suggested
Modi govt should approve bills enhancing BC quota in Telangana: CM Reddy
At Rs 133 crore, Siddhivinayak temple earnings see 16% rise in FY 2024-25
War drama 'Warfare' to release in India on April 11
Civic body in Maharashtra introduces QR code-based complaint redressal system
Several places in Rajasthan likely to remain cloudy for next 48 hours: MeT Department
Lakshyaraj Singh becomes Rajasthan's erstwhile royal family's titular head
Indian stocks recover from Tuesday's bloodbath ahead of Trump reciprocal tariffs announcement
"Certainly hope for meeting to take place": Bangladesh Foreign Secy on prospective PM Modi-Yunus meeting at BIMSTEC Summit
See if school land encroached by mosque, shops illegally: Delhi HC to MCD
INRO Summit 2025: Expanding Horizons for Businesses Across Continents
Powered by MessengerX.io